---
schema_version: "secwatch.filing_event.v1"
accession: "0001636282-25-000104"
form_type: "8-K"
ticker: "SYRE"
cik: "0001636282"
company_name: "Spyre Therapeutics, Inc."
filed_at: "2025-11-04T23:59:59+00:00"
generated_at: "2026-05-17T00:38:37.042076+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Spyre Therapeutics reports positive Phase 1 data for SPY003 with ~85-day half-life; Q3 net loss $11.2M

## Summary
- SPY003 Phase 1 interim results show half-life of ~85 days, supporting potential quarterly or twice annual maintenance dosing.
- SPY003 well tolerated, no serious adverse events; safety profile consistent with anti-IL-23 class.
- Q3 2025 net loss of $11.2M, compared to $69.0M in Q3 2024; R&D expenses $45.2M.
- Pro forma cash $782.7M as of Sep 30, 2025, including $296.5M net from October 2025 public offering.
- Company expects 6 proof-of-concept readouts in 2026 from SKYLINE and SKYWAY Phase 2 trials.

## SEC filing metadata
- accession: 0001636282-25-000104
- form_type: 8-K
- ticker: SYRE
- cik: 0001636282
- company_name: Spyre Therapeutics, Inc.
- filed_at: 2025-11-04T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1636282/000163628225000104/0001636282-25-000104-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1636282/000163628225000104/syre-20251104.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001636282-25-000104
- JSON: https://secwatch.observer/filing/0001636282-25-000104.json
- Plain text: https://secwatch.observer/filing/0001636282-25-000104.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.